Amgen (AMGN) Given Buy Rating at Morgan Stanley
Morgan Stanley restated their buy rating on shares of Amgen (NASDAQ:AMGN) in a research note published on Tuesday morning. They currently have a $213.00 price objective on the medical research company’s stock.
Other analysts also recently issued research reports about the company. Royal Bank of Canada reaffirmed a neutral rating and issued a $193.00 price objective on shares of Amgen in a research note on Monday, September 10th. Jefferies Financial Group reaffirmed a buy rating and issued a $220.00 price objective on shares of Amgen in a research note on Monday, October 1st. Oppenheimer reaffirmed a buy rating and issued a $224.00 price objective on shares of Amgen in a research note on Tuesday, August 28th. Wells Fargo & Co reaffirmed a neutral rating and issued a $197.00 price objective on shares of Amgen in a research note on Wednesday, August 29th. Finally, Citigroup lifted their price objective on Amgen from $200.00 to $204.00 and gave the stock a neutral rating in a research note on Thursday, November 1st. One investment analyst has rated the stock with a sell rating, thirteen have given a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of Hold and a consensus target price of $205.68.
NASDAQ:AMGN opened at $199.01 on Tuesday. The company has a debt-to-equity ratio of 2.05, a quick ratio of 2.84 and a current ratio of 3.08. Amgen has a 1 year low of $163.31 and a 1 year high of $210.19. The company has a market capitalization of $126.02 billion, a price-to-earnings ratio of 15.82, a PEG ratio of 2.05 and a beta of 1.41.
The business also recently announced a quarterly dividend, which will be paid on Friday, December 7th. Stockholders of record on Friday, November 16th will be issued a $1.32 dividend. This represents a $5.28 dividend on an annualized basis and a dividend yield of 2.65%. The ex-dividend date of this dividend is Thursday, November 15th. Amgen’s dividend payout ratio (DPR) is 41.97%.
In other news, SVP Cynthia M. Patton sold 1,777 shares of Amgen stock in a transaction that occurred on Thursday, November 29th. The stock was sold at an average price of $202.88, for a total value of $360,517.76. Following the completion of the transaction, the senior vice president now owns 23,090 shares in the company, valued at approximately $4,684,499.20. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 0.19% of the stock is currently owned by insiders.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Kwmg LLC purchased a new position in Amgen during the 2nd quarter valued at $108,000. Mainstay Capital Management LLC ADV purchased a new position in Amgen during the 2nd quarter valued at $111,000. Polaris Greystone Financial Group LLC bought a new stake in Amgen during the 3rd quarter valued at $166,000. Family Firm Inc. bought a new stake in Amgen during the 2nd quarter valued at $202,000. Finally, Wellington Shields Capital Management LLC bought a new stake in Amgen during the 3rd quarter valued at $202,000. Institutional investors own 76.94% of the company’s stock.
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.
Recommended Story: Dividend Aristocrat Index
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.